Patents
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
09/2004
09/14/2004US6790827 Bioconjugates and delivery of bioactive agents
09/14/2004US6790825 Stimulating secretion of pancreatic juices
09/14/2004US6790463 Peroxidation reaction products of an alkene, such as geraniol; penetrating solvent, such as dimithyl sulfoxide; a dye containing a chelated metal, such as hematoporphyrin; and an aromatic redox compound, such as benzoquinone.
09/14/2004US6790458 Pharmaceutical compositions using semi-solid delivery vehicle
09/14/2004US6790445 Preservatives for vaccines
09/14/2004US6790439 Thrombopoietin compositions
09/14/2004US6790437 Method of treating cancerous tumors with a dendritic-platinate drug delivery system
09/14/2004CA2459869A1 A system for use by compounding pharmacists to produce hormone replacement medicine customized for each consumer
09/14/2004CA2136438C Anthracycline conjugates, their preparation and their use as antitumor agents
09/14/2004CA2073113C Conjugates
09/12/2004CA2458761A1 Prosthesis with sustained release analgesic
09/10/2004WO2004076658A1 Monoclonal antibody, gene encoding the same, hybridoma, medicinal composition and diagnostic reagent
09/10/2004WO2004076644A2 A composition for delivering an agent to a target cell and uses thereof
09/10/2004WO2004076621A2 Compositions of nucleic acids for treating and detecting influenza virus
09/10/2004WO2004076602A1 Method of preventing lipids constituting lipid membrane from degradation and use thereof
09/10/2004WO2004076561A1 Poloxamer emulsion preparations
09/10/2004WO2004076557A1 Biodegradable polyacetals
09/10/2004WO2004076474A2 Polyethylene glycol modified interferon compositions and methods of use thereof
09/10/2004WO2004076471A1 Anti-influenza virus compound comprising biflavonoid-sialic acid glycoside
09/10/2004WO2004076369A2 Antimicrobial active borosilicate glass
09/10/2004WO2004075989A1 Fumed silica embolic compositions
09/10/2004WO2004075923A2 Polymer-factor viii moiety conjugates
09/10/2004WO2004075922A2 Compounds comprising at least one active substance and at least one carrier which are connected by a binding agent, uses thereof and said binding agents
09/10/2004WO2004075921A1 Inclusion complex of artemisinin or derivates thereof with cyclodextrins
09/10/2004WO2004075920A1 Sustained-release pharmaceutical composition for lung administration
09/10/2004WO2004075919A2 Compounds for protein stabilization and methods for their use
09/10/2004WO2004075918A1 Liquid formulations of tumor necrosis factor-binding proteins
09/10/2004WO2004075913A1 Stabilized preparation containing protein
09/10/2004WO2004075900A2 Pharmaceutical formulations comprising sodium laurylsulfate as bitterness masking agent
09/10/2004WO2004075854A2 Microbicidal compositions and method of use
09/10/2004WO2004075834A2 Stabilized pharmaceutical compositions of safingol and methods of using the same
09/10/2004WO2004075824A2 Pharmaceutical compositions for nasal delivery
09/10/2004WO2004075822A2 Pharmaceutical composition for transdermal or transmucosal administration
09/10/2004WO2004075811A2 Subcutaneously-administered ganglioside-based vaccine compositions
09/10/2004WO2004064850A8 Antiviral composition comprising a sulphated glucose polymer and a bacteriostatic agent
09/10/2004WO2004062564A3 Sedative non-benzodiazepine formulations
09/10/2004WO2004058803A3 Peptides that bind of the vegfr-2
09/10/2004WO2004050795A3 Antioxidant-functionalized polymers
09/10/2004WO2004047799A3 Pellets containing non-aqueous fluids and the process for their preparation
09/10/2004WO2004047795A3 Cutaneous application of flupirtine
09/10/2004WO2004043357A3 Method of making, and the use of cytotoxic agents containing elemental selenium
09/10/2004WO2004037208A3 Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
09/10/2004WO2004022128A3 Liquid aerosol formulations and aerosol generating devices and methods for generating aerosols
09/10/2004WO2003053169A8 Soft drink replacer
09/10/2004WO2003003979A3 Methods for the production of purified recombinant human uteroglobin for the treatment of inflammatory and fibrotic conditions
09/10/2004CA2788505A1 Polymer-factor viii moiety conjugates
09/10/2004CA2517369A1 Polymer-factor viii moiety conjugates
09/10/2004CA2517310A1 Stabilized protein-containing formulations_comprising a poloxamer
09/10/2004CA2517104A1 Anti-influenza virus compounds comprising biflavonoid-sialic acid conjugates
09/10/2004CA2517074A1 Nucleic acid molecules, polypeptides, antibodies and compositions containing same useful for treating and detecting influenza virus infection
09/10/2004CA2516552A1 Polyethylene glycol modified interferon compositions and methods of use thereof
09/10/2004CA2516459A1 Pharmaceutical compositions for nasal delivery
09/10/2004CA2516399A1 Pharmaceutical compositions of safingol and methods of using the same
09/10/2004CA2515539A1 Liquid formulations of tumor necrosis factor-binding proteins
09/10/2004CA2515389A1 Monoclonal antibody and gene encoding the same, hybridoma, pharmaceutical compostion, and diagnostic reagent
09/09/2004US20040176749 Insert for the treatment of dry eye
09/09/2004US20040176576 Antibodies against cancer
09/09/2004US20040176569 Regioselective liquid phase pegylation
09/09/2004US20040176476 Pharmaceutical composition
09/09/2004US20040176473 Methods for delivering compounds into a cell
09/09/2004US20040176439 coadministration of agent which exhibits poor or inconsistent oral bioavailability (e.g., paclitaxel, docetaxel or etoposide), and an oral bioavailability-enhancing agent (e.g., cyclosporin A, cyclosporin D, cyclosporin F)
09/09/2004US20040176359 Intranasal Benzodiazepine compositions
09/09/2004US20040176357 Stable, amorphous , lyophilized, parenteral injections comprising olanzapine, solubilizer and stabilizer; bipolar, psychological and neurodegenerative disorders; anxiolytic agents;schizophrenia
09/09/2004US20040176342 Fluticasone lotion having improved vasoconstrictor activity
09/09/2004US20040176328 Encapsulated bioactive bisphosphonate such as alendronate including mono- or diglyceride of caproic or capric acid enhancer or surfactant comprising ethylene oxide-propylene oxide block copolymer
09/09/2004US20040176321 9-Fluoro-6,7-dihydro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid derivatives; basic amino acid or cyclodextrin solubilizer; microbiocide injections
09/09/2004US20040176319 Cellular uptake of bioactive agents
09/09/2004US20040176318 Pretreating with lipophilic substituted saccharide
09/09/2004US20040176312 Treatment of ungual and subungual diseases
09/09/2004US20040176299 Combination of pancreatic cell surface marker binding agent, polypeptide translocation transfer element and enzymatic secretion inhibitor
09/09/2004US20040176281 Pharmaceutical carriers comprised of at least mono- or oligosaccharide and lipidic moiety; intestinal absorption
09/09/2004US20040176270 Use of isocyanate linkers to make hydrolyzable active agent biopolymer conjugates
09/09/2004US20040175703 to be administered by inhalation, infusion, injection, or orally relates to double-stranded ribonucleic acid (dsRNA), and its use in mediating RNA interference in vitro and in vivo; genetic engineering
09/09/2004US20040175437 preventing and treating certain inflammatory diseases, degenerative diseases and viral diseases in mammals
09/09/2004US20040175435 preservative that do not become complexed with, or to a lesser degree than does benzalkonium chloride, cyclodextrin and are not rendered ineffective; chlorite or sorbic acid preservative
09/09/2004US20040175433 using a viscous rather than a liquid footbath performs much better in preventing and combating hoof diseases; active ingredient and a colloid former
09/09/2004US20040175424 Medicine based on anti-hyperglycaemic microcapsules with prolonged release and method for preparing same
09/09/2004US20040175422 excellent storage stability and little tendency to change the release rate of the pharmacologically active substance even after long-term storage; matrix comprising low-melting-point substance and pH-independent water-insoluble polymer
09/09/2004US20040175420 at least one non-ionic or zwitterionic surfactant and dispersant; improves the efficacy and/or potency of the lipase inhibitor; inter-subject variability in efficacy and/or potency is reduced, as well as the frequency and intensity of side effects
09/09/2004US20040175419 controlling crystallization parameters of active ingredient to achieve increased compactability; compacting the active ingredient into a tablet
09/09/2004US20040175418 Teste masking pharmaceutical composition
09/09/2004US20040175416 Pharmaceutical composition for transdermal or transmucous administration
09/09/2004US20040175415 Formulations and methods of delivery of intact tocopheryl succinate to humans
09/09/2004US20040175407 Microorganism coating components, coatings, and coated surfaces
09/09/2004US20040175402 Formulation
09/09/2004US20040175387 O,O'-amidomalonate and N,O-amidomalonate platinum complexes
09/09/2004US20040175374 Therapeutic platelets and methods
09/09/2004US20040175363 Defective recombinant adenovirus; treatment of neurodenerative, cardiovascular, brain, genetic, nervous system and respiratory system disorders; Alzheimer's, Parkinson's, amyotrophic lateral sclerosis (ALS), atherosclerosis, and/or trisomy 2; adult respiratory distress syndrome; anticarcinogenic agents
09/09/2004US20040175353 Cyanoacrylate compositions for prophylactic or therapeutic treatment of diseases manifesting themselves in and/or damage cutaneous tissue
09/09/2004US20040175348 formed by spray-drying a solution of an edible organic acid wherein chitosan is dissolved; storage stability
09/09/2004US20040175342 Process of making and using composition containing oxidation-sensitive hydrophilic active principle and maleic anhydride copolymer
09/09/2004US20040175335 Sunscreen composition
09/09/2004US20040173224 Nicotine salts having improved taste, process for their preparation and their use
09/09/2004DE10309005A1 New conjugates comprising a dipeptidyl peptidase inhibitor linked to a neural endopeptidase inhibitor, e.g. useful for treating diabetes, obesity, growth hormone deficiency, immunosuppression, HIV infection
09/09/2004DE10304988A1 Transdermales Therapeutisches System mit verbessertem Hautklebeverhalten The transdermal therapeutic system with improved skin adhesive behavior
09/09/2004DE10107663B4 Testosteronhaltiges transdermales therapeutisches System, Verfahren zu seiner Herstellung und seine Verwendung Testosterone-containing transdermal therapeutic system, process for its preparation and its use
09/09/2004DE10004790B4 Method for producing sewn or embroidered three-dimensional textile structure utilized for e.g. table cloth, involves connecting points on lattice structure with threads to form thread arrangement under which lattice structure is not visible
09/08/2004EP1454950A1 Pullulan-containing powder, process for producing the same and use thereof
09/08/2004EP1454640A2 Formulations of hyaluronic acid for delivery of osteogenic proteins
09/08/2004EP1454635A1 Tasteless, directly compressible, fast-dissolving complexes and pharmaceutical formulations thereof